The trading price of Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) closed higher on Friday, April 19, closing at $0.53, 3.44% higher than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $3.37 and a 52-week low of $0.13. Over the past month, the stock has gained 4.93% in value.
Brainstorm Cell Therapeutics, Inc., whose market valuation is $36.36 million at the time of this writing, is expected to release its quarterly earnings report May 13, 2024 – May 17, 2024. Investors’ optimism about the company’s current quarter earnings report is understandable.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Brainstorm Cell Therapeutics, Inc. No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest BCLI has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently Hold.
A quick review shows that BCLI’s price is currently -12.86% off the SMA20 and 16.39% off the SMA50. The RSI metric on the 14-day chart is currently showing 49.00, and weekly volatility stands at 23.19%. When measured over the past 30 days, the indicator reaches 21.37%. Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s beta value is currently sitting at 0.32, while the Average True Range indicator is currently displaying 0.10.
To see how Brainstorm Cell Therapeutics, Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: BCLI stock’s performance was 3.44% in the latest trading, and -80.07% in the past year.
An evaluation of the daily trading volume of Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) indicates that the 3-month average is 1.01 million.
Currently, records show that 60.49 million of the company’s shares remain outstanding. The insiders hold 17.86% of outstanding shares, whereas institutions hold 5.92%. However, since the stock’s price has seen 94.87% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
